FDA panel votes against wider use of Amgen drug

WASHINGTON (Reuters) - An advisory panel on Wednesday recommended that U.S. health regulators reject the use of Amgen Inc's drug Xgeva to delay the spread of prostate cancer to the bone, dimming the chance of a wider use for one of the company's key growth drivers.

Source: http://feeds.reuters.com/~r/reuters/healthNews/~3/GnVN2MeqeFM/us-fda-amgen-xgeva-idUSTRE8172G820120208

latest news top news recent news save money travel make money